EXPLORING INSULIN COST-SHARING CAPS FOR PATIENTS WITH PRIVATE COVERAGE
The following information was released by the
Authors:
Nearly 29 million adults in the
Applying a cost-sharing cap on insulin to private insurance coverage, including employer coverage, has been gaining momentum among policymakers. Since 2019, an increasing number of state laws have limited cost-sharing for insulin in state-regulated plans, and a federal insulin cost-sharing cap for consumers with private coverage has advanced in
Background
Insulin affordability has long concerned policymakers. Between 2007 and 2018, the list prices of some forms of insulin increased by more than 260%, according to one study. In Medicare Part D alone, aggregate patient out-of-pocket spending for insulin products quadrupled between 2007 and 2020, according to a KFF analysis.
Examinations have linked high insulin costs, in part, to increasing drug manufacturer list prices and certain contracting and other business practices by pharmacy benefit managers (PBMs). In 2019, the
The committee also stated that the three largest PBMs have significant marketing power to negotiate rebates with drug manufacturers. Rebates are discounts off the list price that PBMs negotiate with drug manufacturers in exchange for preferred placement of the drug on a health plan formulary. The committee determined that, "... the practice of offering rebates in the insulin therapeutic class appears to be contributing to both increasing insulin WAC prices and limited uptake of lower-priced products." This, among other factors, the report concluded, can keep insulin out-of-pocket costs high for individual consumers partly because plan formularies often favor higher-cost insulins (with the highest rebates) while excluding or disadvantaging lower-priced insulins.
Other studies have highlighted insulin affordability issues for those who have to pay for it out of pocket at a high list price before meeting their deductible, when insurance begins to pay, as well as those whose cost sharing is pegged to a high list price (e.g., coinsurance). Additionally, privately insured patients typically pay for insulin based on a negotiated rate that does not reflect manufacturer rebates, which may reduce what a plan pays for the insulin but are not necessarily passed through to the patient.
In the years since these evaluations, federal efforts to lower insulin out-of-pocket costs have progressed, notably the passage of the Inflation Reduction Act of 2022 (IRA). Among other prescription drug cost reforms, the IRA established a cost-sharing cap for a month's supply of any covered insulin for Medicare beneficiaries beginning in 2023. The law limits monthly copayments to the lesser of
Although earlier versions of the IRA would have put the same cap on monthly cost sharing for those in private plans (e.g., employer-sponsored plans and on- and off-Marketplace individual market coverage), this was dropped from the IRA prior to passage. A Peterson-KFF Health System Tracker analysis of 2018 claims data found that a
While those with private coverage do not have the cost-sharing protection that Medicare Part D beneficiaries have,
Voluntary drug manufacturer price reductions starting in 2023 lower the cost of certain insulins. In
Other federal action and state litigation aim to address insulin prices and costs. While congressional actions focused on reducing costs for prescription drugs broadlyincluding a PBM transparency and rebate reform law passed earlier this year and efforts to bring more lower-cost biosimilars to marketlikely impact insulin costs, other activity focused specifically on insulin pricing includes:
Separate state litigation. Some state attorneys general (AGs), cities, school districts, and other plaintiffs have sued the leading insulin manufacturers and PBMs, alleging anticompetitive and/or deceptive practices related to high insulin prices. State AGs in Republican-led and Democratic-led states have filed actions over the past three years, many of which have been consolidated with hundreds of other similar cases in a federal district court. These cases largely allege violations of state antitrust and consumer protection laws, seeking both to stop drug manufacturer and PBM practices that they allege inflate insulin prices, and to secure damages for affected consumers and employers. No major court decisions or settlement agreements have been issued yet in these cases.
Alternative pathways to lower-cost insulin are gaining momentum. New approaches to insulin production and distribution are opening new access points for patients. For instance,
A growing direct-to-consumer sales market gives patients another avenue to purchase insulin at discounted prices, mostly on a cash-pay basis outside of insurance, from online pharmacies such as
State Insulin Cost-Sharing Caps
According to KFF analysis of state laws, as of
Cost-sharing Caps for Those with
Dollar Cap Amounts
The dollar amounts of insulin cost-sharing caps vary by state. While some states have lowered their caps since enacting their first laws, caps currently range from
Dollar Cap Structure
The structure of insulin cost-sharing caps is relevant for people who use multiple insulins each month. While caps in most states are structured as a separate amount for each prescription, at least four states (CO, DE, VT, and WV) currently have aggregate caps that apply to total out-of-pocket spending for all covered insulin products a patient may purchase in a month. (
Drugs and Other Items Covered by Caps
Many state caps apply broadly to prescription drugs containing insulin used to treat diabetes, regardless of form (e.g., vial, pen, inhaled) or type (e.g., rapid-acting, short-acting, intermediate-acting, long-acting). Some states have additional requirements. For example,
Limitations of State Caps
According to KFF analysis of the 2024 Behavioral Risk Factor Surveillance System (BRFSS) data, 8% of privately insured adults have been diagnosed with diabetes, ranging from 4% in the
29 States and DC Have Cost-Sharing Caps on Insulin for
Insulin cost-sharing caps in state-regulated private health plans as of
State-regulated private health plans include individual health insurance, fully insured group plans sponsored by private employers, and self-funded group plans sponsored by state governments. Seventy percent of people with job-based coverage are in self-funded plans sponsored by private employers, which are exempt from most state insurance laws. Unless otherwise indicated, cap amounts are for a 30-day supply.
States with a cross-hatch pattern have a diabetes prevalence among privately insured adults that is higher than the national average of 8%. Only those individuals in state-regulated plans benefit from state cost-sharing caps, though. Data are not available for
KFF analysis of state insulin laws. For diabetes prevalence, KFF analysis of 2024 Behavioral Risk Factor Surveillance System (BRFSS) data
No Cost Sharing for Insulin in Some State ACA Marketplace Plans
In addition to the broadly applicable statutory cost-sharing caps described above, at least three state-based ACA Marketplaces have used their administrative authority to eliminate all cost sharing for specific chronic condition maintenance drugs, including insulin, for certain enrollees. For example, enrollees in specific Marketplace plan types or cost-sharing tiers in the
Out-of-pocket Insulin Caps for the Uninsured and Underinsured
According to KFF's analysis of 2024 BRFSS data, 7% of uninsured adults have been diagnosed with diabetes. Uninsured individuals generally receive less health care than those with insurance. In 2024, 42% of uninsured adults under age 65 with diabetes delayed or avoided receiving needed care due to the cost, compared to 11% of those with insurance. At least three statesCO, ME (until 2027), and MNhave implemented separate affordability programs that cap insulin costs for uninsured, as well as certain underinsured patients.
Affordability Safety
Laws in
Urgent Need Programs
Proposed Federal Insulin Cost-Sharing Cap
Bipartisan federal legislation known as the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2026 would impose a national insulin cost-sharing cap for private insurance and establish a pilot program to assist the uninsured. Similar bills have been introduced in previous years, but this year's was considered and approved by the
A requirement for private plans to cover "selected insulin products." Plans would be required to cover at least one insulin of each dosage form of each insulin type. Plans and insurers make the selection, so coverage of specific insulins would likely differ by plan. The requirement extends to all employer-sponsored health plans (insured and self-funded), including non-Federal governmental plans, as well as individual market plans (including Marketplace plans). The legislation does not apply to non-insulin diabetes medications or supplies.
A
No deductibles would apply before cost sharing starts. Health plans would be prohibited from applying a deductible to their selected insulins. This would apply even to catastrophic plans available on ACA Marketplaces where, currently, enrollees must pay a high deductible (
Selected insulin would be treated as an essential health benefit. The legislation also states that the selected insulin product should be treated "as though such benefits were required to be provided" as an essential health benefit (EHB). Insurers in the individual and small group market are required to cover EHBs and count patient cost sharing for them toward the ACA's required patient out-of-pocket maximum (
Limits on prior authorization for selected insulins. The legislation would prohibit plans and insurers from imposing prior authorization requirements on the selected insulin products except as "clinically justified for safety reasons, to ensure reasonable quantity limits and as specified by the Secretary." While this does not ban prior authorization, it might put new requirements on plans to justify why prior authorization is required for the plan's selected insulins.
New pilot program for the uninsured. The bill would also create a temporary program to help address barriers for uninsured people using insulin. The 5-year,
Changes to increase access to biosimilars. The INSULIN Act also proposes changes to
Policy Considerations
Expanding out-of-pocket caps at the state level, or passing a federal out-of-pocket cap for insulin, could make insulin more affordable for consumers and provide some assurance that their out-of-pocket costs for insulin should not exceed a certain threshold. While the INSULIN Act of 2026 would fill the gaps in the current patchwork of state insulin cost-sharing caps and provide a federal floor of protections, it does not regulate the price of insulin or directly address the current dynamics of manufacturer rebates and formulary placement that may have led to high prices. Some considerations for policymakers include:
The extent to which a federal cap would substantially change what patients with private coverage pay for insulin. In recent years, some studies of state out-of-pocket caps on insulin showed only modest reductions in consumer out-of-pocket costs, possibly because many with private insurance already had relatively low cost sharing for some insulin types. A
Although direct-to-consumer (DTC) options offered by some manufacturers and online pharmacies may provide some insulin users with a less expensive alternative than the proposed
How other federal actions could intersect with the proposed cost-sharing cap and impact insulin prices for privately insured and uninsured consumers. The inclusion of insulin on the Medicare drug price negotiation list, another federal law that will require PBMs to pass through all rebates to health plans sponsored by private employers, and new requirements on PBMs under
The impact of an out-of-pocket insulin cap on enrollees' private insurance premiums and other out-of-pocket costs. Although the


THE AMERICAN DIABETES ASSOCIATION FIGHTS TO MAINTAIN ACCESS TO HEALTH INSURANCE
Advisor News
- Survey: Most Americans still feel prosperous despite economic worries
- SEC settlement would require Tai Lopez, two others, to pay $6.8 million
- The Gen Z money paradox
- NAIFA applauds final SECURE 2.0 regulations
- What will Democrats in Congress do about healthcare and retirement?
More Advisor NewsAnnuity News
- AM Best Affirms Credit Ratings of Global Atlantic Financial Group Limited and Its Subsidiaries
- Best’s Market Segment Report: AM Best Maintains Stable Outlook on US Life/Annuity Insurance Segment
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- Boomers want retirement protection, but their actions don’t match their mindset
- NAIC task force to address LTC riders
More Annuity NewsHealth/Employee Benefits News
- EXPLORING INSULIN COST-SHARING CAPS FOR PATIENTS WITH PRIVATE COVERAGE
- THE AMERICAN DIABETES ASSOCIATION FIGHTS TO MAINTAIN ACCESS TO HEALTH INSURANCE
- Grand jury accuses veteran of making false disability claims that defrauded VA
- States push short-term insurance as healthcare costs climb
- Study Findings on Managed Care Are Outlined in Reports from Massachusetts General Hospital (A RUC Rescue of Primary Care?): Managed Care
More Health/Employee Benefits NewsLife Insurance News
- FORMER PRINCE GEORGE'S COUNTY INSURANCE AGENT SENTENCED FOR FELONY INSURANCE THEFT SCHEME
- AM Best Affirms Credit Ratings of Ameriprise Financial, Inc. and Its Subsidiaries
- AM Best Takes Various Credit Rating Actions on Certain Subsidiaries of Auto-Owners Insurance Group
- AM Best Affirms Credit Ratings of Global Atlantic Financial Group Limited and Its Subsidiaries
- AM Best Downgrades Credit Ratings of CICA Life Insurance Company of America
More Life Insurance News